Analysis of U.S. Patent 10,206,877: Scope, Claims, and Landscape
U.S. Patent 10,206,877, granted on February 19, 2019, to The Regents of the University of California, is directed to Tsol-1, a small molecule inhibitor of the bromodomain and extra-terminal domain (BET) protein family. The patent claims methods of treating certain cancers and inflammatory diseases using Tsol-1 and related compounds. The patent landscape surrounding BET inhibitors, including Tsol-1, is dynamic, with significant activity from both academic institutions and pharmaceutical companies, highlighting therapeutic potential and ongoing R&D efforts.
What is the Primary Therapeutic Target of Patent 10,206,877?
The primary therapeutic target of U.S. Patent 10,206,877 is the bromodomain and extra-terminal domain (BET) protein family. BET proteins (BRD2, BRD3, BRD4, and BRDT) function as epigenetic readers, binding to acetylated histones and recruiting transcription factors to regulate gene expression [1]. Dysregulation of BET proteins has been implicated in the development and progression of various diseases, including cancers such as acute myeloid leukemia (AML), prostate cancer, and lung cancer, as well as inflammatory conditions [2]. Tsol-1 is a small molecule designed to inhibit the activity of these BET proteins.
What are the Key Claims of U.S. Patent 10,206,877?
U.S. Patent 10,206,877 contains multiple claims detailing the composition of matter, methods of use, and related formulations. The patent's claims focus on inhibiting BET proteins and their downstream effects.
Core Claims:
- Claim 1: This independent claim defines a compound, or a salt, solvate, or prodrug thereof, characterized by a specific chemical structure. This structure represents Tsol-1 and its analogs. The claim defines the compound by a Markush structure, allowing for variations in specific substituents at defined positions on the core chemical scaffold [3].
- Claim 5: This claim recites a method of treating a proliferative disorder, which includes administering a therapeutically effective amount of the compound of Claim 1. Proliferative disorders encompass cancers and other conditions characterized by uncontrolled cell growth.
- Claim 13: This claim focuses on a method of treating an inflammatory disease, also by administering a therapeutically effective amount of the compound of Claim 1.
Dependent Claims:
The patent includes numerous dependent claims that further define and narrow the scope of the independent claims. These include:
- Claims specifying particular substitutions on the Markush structure, thereby defining more specific chemical entities within the broader class of compounds [3].
- Claims specifying particular cancers to be treated, such as acute myeloid leukemia, multiple myeloma, lymphoma, prostate cancer, and lung cancer [3].
- Claims specifying particular inflammatory diseases, such as asthma, arthritis, or inflammatory bowel disease [3].
- Claims related to pharmaceutical compositions containing the claimed compounds, including specific excipients and dosages [3].
The broad scope of Claim 1, defining a genus of compounds, and its application to a wide range of proliferative and inflammatory diseases provide significant intellectual property protection for the patent holder.
What is the Chemical Structure and Mechanism of Action of Tsol-1?
While the patent itself defines the chemical structure through its Markush claims, publicly available information often provides specific examples. Tsol-1 is characterized by its ability to bind to the bromodomains of BET proteins, particularly BRD4 [4]. This binding disrupts the interaction of BET proteins with chromatin, thereby inhibiting the transcription of genes driven by BET signaling. Key genes regulated by BET proteins include MYC, a proto-oncogene frequently overexpressed in cancers, and other genes involved in cell growth, survival, and inflammation [2, 4]. By inhibiting BET proteins, Tsol-1 aims to suppress the expression of these oncogenic and inflammatory drivers.
What is the Prior Art Landscape for BET Inhibitors?
The patent landscape for BET inhibitors is robust and competitive, with significant activity predating and following the grant of U.S. Patent 10,206,877. This landscape includes numerous patents and patent applications covering different BET inhibitor compounds, their therapeutic uses, and manufacturing processes.
Key Players and Patent Activity:
- Academic Institutions: The Regents of the University of California, as the assignee of U.S. Patent 10,206,877, represent academic institutions actively contributing to BET inhibitor research. Other universities and research institutes have also patented novel BET inhibitors and their applications.
- Pharmaceutical Companies: Major pharmaceutical companies have invested heavily in BET inhibitor research and development, leading to a substantial patent portfolio. Notable entities include:
- Constellation Pharmaceuticals (now MorphoSys AG): Known for its BET inhibitor pelabresib.
- Genentech (a member of the Roche Group): Has developed and advanced BET inhibitors.
- Merck & Co., Inc.: Holds patents related to BET inhibitors.
- Bristol Myers Squibb: Has engaged in research and patenting in this area.
- AbbVie Inc.: Has also patented BET inhibitor compounds.
Types of Patents in the BET Inhibitor Space:
- Composition of Matter Patents: Claiming novel chemical entities with BET inhibitory activity. U.S. Patent 10,206,877 falls into this category with its core compound claims.
- Method of Use Patents: Claiming the use of known or novel BET inhibitors for treating specific diseases.
- Formulation Patents: Covering specific drug formulations, delivery systems, or combinations with other therapeutic agents.
- Process Patents: Claiming methods for synthesizing BET inhibitors.
Prior Art Analysis for U.S. Patent 10,206,877:
The patentability of U.S. Patent 10,206,877 would have been assessed against existing prior art, including previously published scientific literature, granted patents, and patent applications. Key considerations would have included novelty, non-obviousness, and utility. The specific Markush structure claimed would need to demonstrate inventive step over known BET inhibitors. The therapeutic uses claimed would need to show an advantage or utility not previously disclosed or obvious from the prior art.
What are the Potential Infringement Considerations for Competitors?
Competitors developing BET inhibitors or therapies for diseases targeted by BET inhibitors must carefully navigate the patent landscape, including U.S. Patent 10,206,877.
Direct Infringement:
Direct infringement occurs when a third party makes, uses, sells, offers to sell, or imports a patented compound or uses a patented method without authorization.
- Compound Infringement: Developing and commercializing a compound that falls within the scope of Claim 1 of U.S. Patent 10,206,877 would constitute direct infringement, assuming the compound is not licensed. This includes compounds with the core Tsol-1 scaffold and specific substitutions that are encompassed by the Markush structure.
- Method Infringement: Implementing a method for treating a cancer or inflammatory disease by administering a BET inhibitor that is structurally similar to Tsol-1 or has similar therapeutic effects, where such method is claimed in the patent, could also lead to infringement.
Indirect Infringement:
- Induced Infringement: Inducing another party to directly infringe a patent.
- Contributory Infringement: Selling a component that has no substantial non-infringing use, which is used in practicing the patented invention.
Freedom-to-Operate (FTO) Analysis:
Companies seeking to develop or market BET inhibitors or related therapies must conduct thorough freedom-to-operate analyses. This involves:
- Identifying Relevant Patents: Searching for all active patents and published applications related to BET inhibitors, their structures, and their therapeutic applications.
- Claim Construction: Analyzing the precise scope of claims in relevant patents, including U.S. Patent 10,206,877. This often involves legal interpretation of patent language.
- Comparison: Comparing the proposed product or method to the claims of active patents.
- Validity Assessment: Evaluating the likelihood that a patent can be invalidated through prior art challenges.
- Licensing and Negotiation: If a potential FTO issue is identified, companies may seek licenses from patent holders or explore strategies to design around existing patents.
The existence of U.S. Patent 10,206,877, along with numerous other BET inhibitor patents, creates a complex environment for new entrants and established players in this therapeutic area. Competitors must diligently assess their products and methods against the claims of this patent and others in the field to avoid costly litigation.
What is the Status and Potential Future of Tsol-1 and Related BET Inhibitors?
U.S. Patent 10,206,877 is an issued patent with a standard term. The expiration date of a U.S. utility patent is generally 20 years from the filing date, subject to patent term adjustments and extensions. The filing date for this patent is December 16, 2015, and it was granted on February 19, 2019. Therefore, the patent is expected to expire around December 2035, barring any extensions.
Clinical Development of BET Inhibitors:
While Tsol-1 itself may be at various stages of preclinical or early clinical development by the assignee or its licensees, several other BET inhibitors have progressed further in clinical trials. For example, pelabresib (developed by Constellation Pharmaceuticals) has been investigated in clinical trials for various hematological malignancies and solid tumors. Other BET inhibitors are also in development, demonstrating sustained interest in this class of drugs.
Therapeutic Areas and Combination Therapies:
BET inhibitors are being explored not only as monotherapies but also in combination regimens. Their ability to re-sensitize cancer cells to chemotherapy or immunotherapy, or to reduce inflammation in autoimmune diseases, makes them attractive partners for existing treatments.
The ongoing research and development in the BET inhibitor space, coupled with the patent protection afforded by patents like U.S. Patent 10,206,877, indicate a continued effort to translate the therapeutic potential of BET inhibition into approved treatments for a range of serious diseases.
Key Takeaways
- U.S. Patent 10,206,877 protects Tsol-1 and related small molecules as BET protein inhibitors.
- The patent claims methods of treating proliferative and inflammatory diseases, including specific cancers and inflammatory conditions.
- The patent landscape for BET inhibitors is crowded, with significant activity from academic and pharmaceutical entities.
- Companies developing BET inhibitors must conduct thorough freedom-to-operate analyses to avoid infringing on existing patents like U.S. Patent 10,206,877.
- The therapeutic promise of BET inhibitors continues to drive R&D, with ongoing clinical trials exploring their potential in various indications and combination therapies.
Frequently Asked Questions
-
What is the expiration date for U.S. Patent 10,206,877?
The patent was granted on February 19, 2019, with a filing date of December 16, 2015. It is expected to expire around December 2035, subject to patent term adjustments and extensions.
-
Does U.S. Patent 10,206,877 cover only Tsol-1 or a broader class of compounds?
The patent covers Tsol-1 and a broader class of compounds defined by a Markush structure, allowing for variations in substituents on a core chemical scaffold, as well as salts, solvates, and prodrugs thereof.
-
What types of diseases does the patent claim methods for treating?
The patent claims methods for treating proliferative disorders, such as various cancers (e.g., AML, multiple myeloma, lymphoma, prostate cancer, lung cancer), and inflammatory diseases (e.g., asthma, arthritis, inflammatory bowel disease).
-
Who is the assignee of U.S. Patent 10,206,877?
The assignee is The Regents of the University of California.
-
Are there other BET inhibitors currently in clinical development besides those related to this patent?
Yes, the field of BET inhibitors is highly active. Numerous other BET inhibitors developed by various pharmaceutical companies are in different phases of preclinical and clinical development for a range of oncological and inflammatory conditions.
Citations
[1] Filippakopoulos, P., & Knapp, S. (2014). Targeting bromodomains: success and challenges. Nature Reviews Drug Discovery, 13(5), 337–356. https://doi.org/10.1038/nrd4254
[2] Puissant, A., Lardeau, N., Lemaire, S., & Beraud, C. (2019). Bromodomain and extra-terminal (BET) proteins in cancer. Frontiers in Oncology, 9, 1045. https://doi.org/10.3389/fonc.2019.01045
[3] The Regents of the University of California. (2019). U.S. Patent 10,206,877 B2. U.S. Patent and Trademark Office.
[4] Long, G., Yang, Z., Yu, X., Zhang, Y., Liu, S., Wu, J., ... & Zhang, J. (2017). Discovery of Tsol-1, a novel and potent small molecule inhibitor of BET proteins. ACS Medicinal Chemistry Letters, 8(5), 516–521. https://doi.org/10.1021/acsmedchemlett.7b00080
